Evaluating the Effectiveness of Pegbelfermin in <scp>MASH</scp>‐Associated Hepatic Fibrosis A Meta‐Analysis and Systematic Review of Randomized Controlled Trials
Pegbelfermin, a promising therapy for MASH fibrosis, has demonstrated effectiveness at 10 mg, significantly improving MASH and biomarkers including adiponectin and PRO-C3, while maintaining a generally safe profile.
Authors
- Ammad Javaid Chaudhary
- Babu P. Mohan (ORCID: https://orcid.org/0000-0002-9512-8693)
- Fariha Hasan (ORCID: https://orcid.org/0000-0001-9897-2745)
- Syeda Kanza Kazmi (ORCID: https://orcid.org/0000-0001-6386-6221)
- Christina Tofani (ORCID: https://orcid.org/0000-0001-6994-7663)
- Manesh Kumar Gangwani (ORCID: https://orcid.org/0000-0002-3931-6163)
- Muhammad Shahzil (ORCID: https://orcid.org/0000-0002-4010-7545)
- Muhammad Ali Khaqan
- Kathy N. Williams (ORCID: https://orcid.org/0000-0002-9770-9336)
- Umm-e-Salma Shabbar
- Muhammad Faisal (ORCID: https://orcid.org/0000-0002-2748-0054)
Institutions
- John H. Stroger, Jr. Hospital of Cook County (US)
- Cooper University Hospital (US)
- Henry Ford Hospital (US)
- Dow University of Health Sciences (PK)
- Penn State Milton S. Hershey Medical Center (US)
- University of Toledo (US)
Publication Details
- Journal
- JGH Open
- Published
- 2025-03-01
- DOI
- https://doi.org/10.1002/jgh3.70131
- Primary Topic
- Fibroblast Growth Factor Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00